AYTU BIOPHARMA, INC Impairment of Intangible Assets, Finite-lived
AYTU BIOPHARMA, INC (AYTU) reported Impairment of Intangible Assets, Finite-lived of $3.00 million for the 12-month period ending 2023-06-30, per its 10-K filed 2024-09-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsFinitelived · last filed 2024-09-26
- AYTU BIOPHARMA, INC impairment of intangible assets, finite-lived for the quarter ending 2022-09-30 was $0.00.
- AYTU BIOPHARMA, INC impairment of intangible assets, finite-lived for the quarter ending 2022-06-30 was $0.00, a 100.00% decline year-over-year.
- AYTU BIOPHARMA, INC impairment of intangible assets, finite-lived for the quarter ending 2022-03-31 was $4.90M, a 13.95% increase year-over-year.
- AYTU BIOPHARMA, INC impairment of intangible assets, finite-lived for the quarter ending 2021-06-30 was $8.53M.
- AYTU BIOPHARMA, INC impairment of intangible assets, finite-lived for fiscal 2023 was $3.00M, a 38.78% decline from fiscal 2022.
- AYTU BIOPHARMA, INC impairment of intangible assets, finite-lived for fiscal 2022 was $4.90M, a 61.79% decline from fiscal 2021.
- AYTU BIOPHARMA, INC impairment of intangible assets, finite-lived for fiscal 2021 was $12.82M, a 6476.92% increase from fiscal 2020.
- AYTU BIOPHARMA, INC impairment of intangible assets, finite-lived for fiscal 2020 was $195.00K.
| Period end | Impairment of Intangible Assets, Finite-lived 3 month | Impairment of Intangible Assets, Finite-lived 3 month as first filed | Impairment of Intangible Assets, Finite-lived 6 month | Impairment of Intangible Assets, Finite-lived 9 month | Impairment of Intangible Assets, Finite-lived 12 month |
|---|---|---|---|---|---|
| 2023-06-30 | $3.00M 10-K · filed 2024-09-26 | ||||
| 2022-09-30 | $0.00 10-Q/A · filed 2023-02-21 | $0.00 derived: sum of 2 quarters · filed 2023-10-12 | $4.90M derived: sum of 3 quarters · filed 2023-10-12 | ||
| 2022-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-10-12 | $4.90M derived: sum of 2 quarters · filed 2023-10-12 | $4.90M 10-K · filed 2023-10-12 | ||
| 2022-03-31 | $4.90M 10-Q · filed 2022-05-16 | $4.90M 10-Q · filed 2022-05-16 | |||
| 2021-06-30 | $8.53M derived: 10-K 12 month − 10-Q 9 month · filed 2021-09-28 | $12.82M derived: sum of 2 quarters · filed 2022-05-16 | $12.82M 10-K · filed 2021-09-28 | ||
| 2021-03-31 | $4.30M 10-Q · filed 2022-05-16 | $4.29M 10-Q · filed 2021-05-17 | $4.30M 10-Q · filed 2022-05-16 | ||
| 2020-06-30 | $195.00K 10-K · filed 2021-09-28 | ||||
| 2019-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-09-26 | $0.00 derived: sum of 2 quarters · filed 2019-09-26 | $0.00 10-K · filed 2019-09-26 | ||
| 2019-03-31 | $0.00 10-Q · filed 2019-05-14 | $0.00 10-Q · filed 2019-05-14 | |||
| 2018-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-09-26 | $1.86M derived: sum of 2 quarters · filed 2019-09-26 | $1.86M 10-K · filed 2019-09-26 | ||
| 2018-03-31 | $1.86M 10-Q · filed 2019-05-14 | $1.86M 10-Q · filed 2019-05-14 | |||
| 2017-06-30 | $1.27M 10-K · filed 2018-09-06 | ||||
| 2016-06-30 | $7.50M 10-K · filed 2017-08-31 | ||||
| 2015-06-30 | $0.00 10-K · filed 2016-09-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |